Q BioMed Inc. (QBIO) financial statements (2021 and earlier)

Company profile

Business Address 366 MADISON AVE.
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End November 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

11/30/2020
11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:0031200
Cash and cash equivalents0031100
Other undisclosed cash, cash equivalents, and short-term investments    1  
Prepaid expense  00   
Other undisclosed current assets00  (1)  
Total current assets:0031100
Noncurrent Assets
Intangible assets, net (including goodwill)001000 
Intangible assets, net (excluding goodwill)001000 
Other undisclosed noncurrent assets   (0)(0)(0) 
Total noncurrent assets:001    
TOTAL ASSETS:1131100
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2200000
Accounts payable11    0
Accrued liabilities11  0  
Interest and dividends payable000 0  
Other undisclosed accounts payable and accrued liabilities  0000 
Debt03  00 
Due to related parties00000  
Other undisclosed current liabilities0 0 3  
Total current liabilities:2500300
Noncurrent Liabilities
Liabilities, other than long-term debt, including:  3 0  
Other undisclosed liabilities, other than long-term debt  3 0  
Other undisclosed noncurrent liabilities 0     
Total noncurrent liabilities: 03 0  
Total liabilities:2630400
Stockholders' equity
Stockholders' equity attributable to parent, including:(1)(5)(0)0(2)(0)0
Common stock0000000
Additional paid in capital48373223610
Accumulated deficit(56)(42)(32)(23)(8)(1)(0)
Other undisclosed stockholders' equity attributable to parent7      
Total stockholders' equity:(1)(5)(0)0(2)(0)0
TOTAL LIABILITIES AND EQUITY:1131100

Income statement (P&L) ($ in millions)

11/30/2020
11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
Revenues0      
Cost of revenue(0)      
Cost of goods and services sold(0)      
Gross profit:(0)      
Operating expenses(13)(8)(9)(12)(6)(1)(0)
Other operating expense, net
(Other Expenses)
   (2)(1)(0) 
Operating loss:(13)(8)(18)(29)(14)(1)(0)
Nonoperating expense
(Other Nonoperating expense)
 (2)     
Interest and debt expense(0)(1)(1)0(0)(0) 
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Loss before gain (loss) on sale of properties:(13)(12)(19)(29)(15)(1)(0)
Other undisclosed net income 12014160 
Net income (loss):(13)(10)1(15)1(1)(0)
Other undisclosed net loss attributable to parent(0) (10) (8)  
Net loss attributable to parent:(13)(10)(9)(15)(7)(1)(0)
Preferred stock dividends and other adjustments(1)      
Other undisclosed net income available to common stockholders, basic  242914  
Net income (loss) available to common stockholders, diluted:(14)(10)15157(1)(0)

Comprehensive Income ($ in millions)

11/30/2020
11/30/2019
11/30/2018
11/30/2017
11/30/2016
11/30/2015
11/30/2014
Net income (loss):(13)(10)1(15)1(1)(0)
Comprehensive income (loss), net of tax, attributable to parent:(13)(10)1(15)1(1)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: